Shattuck Labs to Present at TIGIT Therapies Digital Summit 2021
02 December 2021 - 11:17PM
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune disease with three
ongoing Phase 1 clinical trials, today announced its presentation
at the TIGIT Therapies Digital Summit 2021 being held
virtually December 7 – 9, 2021.
Presentation DetailsPresentation Title:
LIGHTing the Way for TIGIT Blockade in CPI Refractory
TumorsPresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief
Executive OfficerDate: December 9, 2021Time: 9:30 a.m.
ESTLocation: https://tigit-therapies.com/
The presentation will be available for download on
the Events & Presentations section of the company’s
website and also will be available to registered participants
of the TIGIT Therapies Digital Summit 2021.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune disease. Compounds
derived from Shattuck’s proprietary Agonist Redirected Checkpoint,
ARC®, platform simultaneously inhibit checkpoint molecules and
activate costimulatory molecules within a single therapeutic. The
company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to
block the CD47 immune checkpoint and simultaneously agonize the
CD40 pathway, is being evaluated in two Phase 1 trials. A second
product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in
a Phase 1 trial in solid tumors or lymphomas. Additionally, the
company is advancing a proprietary Gamma Delta T Cell Engager,
GADLEN™, platform, which is designed to bridge gamma delta T cells
to tumor antigens for the treatment of patients with cancer.
Shattuck has offices in both Austin, Texas and Durham, North
Carolina. For more information, please visit:
www.ShattuckLabs.com.
Investor Contact: Conor RichardsonSenior
Director, Finance & Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Media Contact:Stephanie Ascher Managing
DirectorStern Investor Relations,
Inc.Stephanie.ascher@sternir.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024